Basel is the most popular Swiss location for headquarters
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.
Novartis global headquarter in Basel (img: Mark Niedermann)
Last year, 912 international companies established their headquarters abroad according to an article by fDi Intelligence on the new rankings. fDi Intelligence has listed the top 30 European locations for headquarters in relation to the number of inhabitants based on the figures. While first place is taken by Dublin, Basel is the best-placed Swiss city at number eight. Geneva is also listed in 19th place.
The list generally illustrates the prevailing position of sites in the United Kingdom. As such, after Dublin and Amsterdam, come Reading and Warwick. Galway in Ireland takes fifth place above Vantaa in Finland. Cork in Ireland (7th), London (9th) and Luxembourg round off the top ten. Munich (17th), Dusseldorf (20th) and Frankfurt (29th) are other German-speaking cities to make it into the top 30.
Data from 2015 to 2019 was considered to create the list. For this, the investments required to establish the headquarters per 100,000 inhabitants of the respective city were used as well as other capital investments and the creation of jobs per 100,000 inhabitants.
Share this article
You may also be interested in
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More